Compare AIRT & HYFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRT | HYFT |
|---|---|---|
| Founded | 1980 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.1M | 66.8M |
| IPO Year | 2018 | 2017 |
| Metric | AIRT | HYFT |
|---|---|---|
| Price | $33.95 | $1.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 13.1K | ★ 128.2K |
| Earning Date | 02-13-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1393.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $286,834,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $29.18 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.98 | N/A |
| 52 Week Low | $18.35 | $0.99 |
| 52 Week High | $35.00 | $3.00 |
| Indicator | AIRT | HYFT |
|---|---|---|
| Relative Strength Index (RSI) | 61.35 | 52.88 |
| Support Level | $20.19 | $1.40 |
| Resistance Level | $34.74 | $1.47 |
| Average True Range (ATR) | 1.80 | 0.08 |
| MACD | 0.24 | 0.01 |
| Stochastic Oscillator | 100.00 | 72.00 |
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include overnight air cargo, ground support equipment, commercial aircraft, engines and parts, digital solutions, and regional airline. The company generates maximum revenue from the overnight air cargo segment.
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.